Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Abstract

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

2008 Massachusetts Medical Society

Figures

Figure 1. PET Scans Obtained before T-Cell Infusion and 2 Months after Infusion

Preinfusion positron-emission tomography (PET) reveals hypermetabolic lesions in the right lung and the left inguinal–iliac node that are consistent with metastases (arrowheads); the lesions colocalized to tumor nodules on computed tomography (CT). After infusion with NY-ESO-1–specific CD4+ T cells, PET scans show that the tumor nodules have regressed, and no evidence of disease can be detected. Uptake in liver, spleen, and bladder represents normal background signal and did not colocalize to any lesions on CT scans.

Figure 2. Persistence of Transferred NY-ESO-1–Specific CD4+ T-Cell Clones In Vivo

Quantitative polymerase-chain-reaction (PCR) assay with the use of clone-specific primers flanking the TCR–CDR3 region was used to determine the frequency of infused CD4+ T-cell clones among peripheral-blood mononuclear cells (PBMCs) in samples collected before infusion and at intervals after infusion until day 90. Results are represented as the number of T-cell clones per 1 million PBMCs and as a percentage of the total number of PBMCs at peak points and low points. As expected, the NY-ESO-1–specific CD4+ T-cell clone is undetectable in preinfusion PBMCs (sensitivity of detection, 1:100,000 cells). After infusion, the frequency of the infused CD4+ T-cell clone in vivo increased to almost 2% of all PBMCs and fluctuated between 0.7 and 3.0% during the next 12 weeks. The I bars denote standard errors.

Figure 3. Augmentation of T-Cell Responses to Melanoma-Associated Tumor Antigens

Antigen-specific T-cell responses to melanoma antigen recognized by T cells (MART-1), melanoma antigen 3 (MAGE-3), NY-ESO-1, and glycoprotein 100 (GP100) were evaluated in samples of peripheral-blood mononuclear cells (PBMCs) collected before infusion and at time points up to 12 weeks after infusion. Autologous dendritic cells (DCs) that were transfected with RNA-encoding tumor antigen were used to stimulate PBMCs in enzyme-linked immunospot assays. The frequency of the antigen-specific response is presented as the number of reactive spots per 100,000 PBMCs (squares). Parallel wells with DCs transfected with control RNA were used at each time point (diamonds). Each data point is an average of the values from triplicate wells. After infusion, marked elevations in antigen-specific T-cell responses were observed for MAGE-3 (Panel A), MART-1 (Panel B), and NY-ESO-1 (Panel C) but not for GP100 (Panel D). The I bars denote standard errors.